Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MH004 Ointment in mild to moderate atopic dermatitis
NCT07185282Phase 3Completed
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tofacitinib etocomil in atopic dermatitis (AD), sponsored by Minghui Pharmaceutical, Inc.. Started Jun 2023; status: completed.
02
Drugs
tofacitinib etocomil
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07185282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185282.